Oncologic outcomes following radical prostatectomy with intraoperative cell salvage

Gorin, Michael A.; Eldefrawy, Ahmed; Manoharan, M.; Soloway, Mark S.

doi:10.1007/s00345-011-0746-4

Cited by 21 publications

(34 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No adverse effects were detected in the patients who received salvaged blood and there was no significant difference in the survival rates between IOCS and non-IOCS groups [15,19,31,35]. The patients receiving IOCS were found to be at least equal or superior in terms of biochemical or pathological recurrence when compared to non-IOCS groups [15,19,30,32].…”

Section: Discussionmentioning

confidence: 55%

“…All these studies showed that reinfusion of salvaged blood could reduce ABT requirements while the clinical outcomes of the patients who received salvaged blood were the same as those who did not [13,17,33,34]. No adverse effects were detected in the patients who received salvaged blood and there was no significant difference in the survival rates between IOCS and non-IOCS groups [15,19,31,35]. The patients receiving IOCS were found to be at least equal or superior in terms of biochemical or pathological recurrence when compared to non-IOCS groups [15,19,30,32].…”

Section: Discussionmentioning

confidence: 84%

“…advanced cellular evidence study, surgical oncologists in some other specialities were bold enough to proceed to clinical studies. They transfused salvaged blood in patients undergoing gynaecological [13,28,29] and urological cancer surgeries [14,15,19,20,[30][31][32][33]. All these studies showed that reinfusion of salvaged blood could reduce ABT requirements while the clinical outcomes of the patients who received salvaged blood were the same as those who did not [13,17,33,34].…”

Section: Discussionmentioning

confidence: 92%

“…Despite the above fact, evidence has accumulated supporting the use of IOCS in different surgical disciplines, i.e. gynaecological, hepatobiliary, gastrointestinal, urological and lung cancer surgery [12][13][14][15][16][17][18][19][20][21]. Other studies provided evidence that if leucocyte depletion filter (LDF) is added, the combination could eliminate all tumour cells from salvaged blood, rendering it safe [3,9,22,23].…”

Section: Introductionmentioning

confidence: 93%

See 3 more Smart Citations

Are we ready for the use of intraoperative salvaged blood in metastatic spine tumour surgery?

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 55%

Section: Discussionmentioning

confidence: 84%

Section: Discussionmentioning

confidence: 92%

Section: Introductionmentioning

confidence: 93%

See 2 more Smart Citations

Are we ready for the use of intraoperative salvaged blood in metastatic spine tumour surgery?

et al. 2015

View full text Add to dashboard Cite

show abstract

“…There is, however, emerging evidence of the successful employment of autotransfusion in cancer surgery outside spine and orthopaedic surgery, namely gynaecological, 36 Overall Chen et al 22 Street et al 23 Sakaura et al 20 Bilsky et al 17 Tanaka et al 25 Xu et al 26 Holman et al 12 Broaddus et al 13 Berkefeld et al 15 Shi et al 16 Cho and Sung 24 Demura et al 27 Bauer et al 14 Schmidt et al 28 Olerud et al 11 Guzman et al 21 Manke et al 19 Abe gastrointestinal, 37 hepatobiliary 38 and urological cancer surgery. 39,40 However, there are no previous reports of the use of autotransfusion in spinal tumour surgery.…”

Section: Discussionmentioning

confidence: 99%

Blood loss in spinal tumour surgery and surgery for metastatic spinal disease

Chen

Tai

Nayak

et al. 2013

The Bone & Joint Journal

View full text Add to dashboard Cite

There is currently no consensus about the mean volume of blood lost during spinal tumour surgery and surgery for metastatic spinal disease. We conducted a systematic review of papers published in the English language between 31 January 1992 and 31 January 2012. Only papers that clearly presented blood loss data in spinal surgery for metastatic disease were included. The random effects model was used to obtain the pooled estimate of mean blood loss. We selected 18 papers, including six case series, ten retrospective reviews and two prospective studies. Altogether, there were 760 patients who had undergone spinal tumour surgery and surgery for metastatic spinal disease. The pooled estimate of peri-operative blood loss was 2180 ml (95% confidence interval 1805 to 2554) with catastrophic blood loss as high as 5000 ml, which is rare. Aside from two studies that reported large amounts of mean blood loss (> 5500 ml), the resulting funnel plot suggested an absence of publication bias. This was confirmed by Egger's test, which did not show any small-study effects (p = 0.119). However, there was strong evidence of heterogeneity between studies (I(2) = 90%; p < 0.001). Spinal surgery for metastatic disease is associated with significant blood loss and the possibility of catastrophic blood loss. There is a need to establish standardised methods of calculating and reporting this blood loss. Analysis should include assessment by area of the spine, primary pathology and nature of surgery so that the amount of blood loss can be predicted. Consideration should be given to autotransfusion in these patients.

show abstract

Sicherheit der maschinellen Autotransfusion in der Tumorchirurgie

et al. 2020

View full text Add to dashboard Cite

Zusammenfassung Hintergrund Fremdbluttransfusionen sind bei vielen onkologischen Eingriffen durch die Anwendung der maschinellen Autotransfusion (MAT) vermeidbar. Es ist fraglich, ob mit dem Einsatz von Leukozytendepletionsfiltern (LDF) eine ähnliche Sicherheit wie bei der Bestrahlung des autologen Blutprodukts hinsichtlich der Vermeidung von Rezidiven erreicht sowie damit eine einfachere und flächendeckendere Versorgung werden kann. Ziele der vorliegenden Übersichtsarbeit waren die Neubeurteilung der vorausgegangenen Metaanalyse aus dem Jahr 2012 aufgrund der seitdem aktualisierten Datenlage und die Ermittlung der Sicherheit von LDF zur Elimination von Tumorzellen. Material und Methode In dem systematischen Review wurden alle Studienpublikationen integriert, die über die gängigen Online-Bibliotheken zugängig sind sowie die Rezidivrate, Letalität, den Transfusionsbedarf und die Krankenhausverweildauer nach dem Einsatz von MAT ohne Bestrahlung mit oder ohne LDF zum Inhalt haben. Die Evidenz wurde mithilfe der „Grades-of-recommendations“(GRADE)-Methodik beurteilt. Ergebnisse Es fanden sich 7 neue Observationsstudien und insgesamt 7 Metaanalysen aus Teilbereichen der Onkochirurgie. Die Evidenz ist gering. Insgesamt wurden 27 Observations- und Kohortenstudien in eine Metaanalyse eingeschlossen. Bei der Versorgung von Patienten mit unfiltriertem oder leukozytendepletiertem Eigenblut war die Rezidivrate verringert („odds ratio“ [OR] 0,71, 95 %-Konfidenzintervall [95 %-KI] 0,58–0,86) im Vergleich zu nichttransfundierten Patienten sowie mit Fremdblut oder gelagertem Eigenblut versorgten Patienten. Letalität und Krankenhausverweildauer sind gegenüber der Versorgung mit Fremdblut- und der Eigenblutspende unverändert. Die Transfusionsrate ist wegen eines erheblichen Selektionsbias und großer Heterogenität nicht beurteilbar. Zur LDF fanden sich 14 Studien (davon 5 In-vitro-Studien). Die Sicherheit der Leukozytendepletion ist durch die Elimination von Tumorzellen im Bereich von 99,6–99,9 % gegeben. Schlussfolgerung Randomisierte Studien zum Vergleich von MAT und Fremdbluttransfusion als auch von LDF und Bestrahlung sind wünschenswert, aber nicht verfügbar. Im Vergleich zu homolog oder nichttransfundierten Patienten existiert keine Evidenz für eine erhöhte Tumorrezidivrate oder ein schlechteres Outcome der Patienten, bei denen MAT während der Tumorchirurgie ohne Bestrahlung des autologen Blutes eingesetzt wurde. Mit der MAT und der anschließenden Leukozytendepletion ist eine Methode zur Vermeidung von Fremdblut verfügbar, die der Bestrahlung vergleichbar sicher, aber einfacher und deshalb effektiver ist.

show abstract

Oncologic outcomes following radical prostatectomy with intraoperative cell salvage

Cited by 21 publications

References 22 publications

Are we ready for the use of intraoperative salvaged blood in metastatic spine tumour surgery?

Are we ready for the use of intraoperative salvaged blood in metastatic spine tumour surgery?

Blood loss in spinal tumour surgery and surgery for metastatic spinal disease

Sicherheit der maschinellen Autotransfusion in der Tumorchirurgie

Contact Info

Product

Resources

About